Pituitary Radiotherapy for Cushing’s Disease

Marco Losa  Piero Picozzi  Maria Grazia Redaelli  Andrea Laurenzi  Pietro Mortini

Pituitary Unit of the Department of Neurosurgery, Istituto Scientifico San Raffaele, Università Vita-Salute, Milano, Italy

Key Words
Radiotherapy • Radiosurgery • Pituitary neoplasm • Pituitary surgery • Adrenocorticotropin • Cortisol

Abstract

Background: The treatment of choice for Cushing’s disease is pituitary surgery. Second-line treatments include repeat pituitary surgery, radiation therapy, medical therapy, and bilateral adrenalectomy. The most used modalities to irradiate patients with Cushing’s disease include fractionated radiotherapy and single-dose Gamma Knife. We aim to review the efficacy and safety of radiotherapy in patients with persistent or recurring Cushing’s disease.

Results: Remission of Cushing’s disease after radiotherapy ranges from 42 to 83%. There seems to be no clear difference according to the technique of radiation used. Most patients experience remission of disease within 3 years from treatment, with only few cases reaching normal cortisol secretion after a longer follow-up. Control of tumor growth varies from 93 to 100%. Severe side effects of radiotherapy, such as optic neuropathy and radionecrosis, are uncommon. New-onset hypopituitarism is the most frequent side effect of radiation, occurring in 30–50% of patients treated by fractionated radiotherapy while it has been reported in 11–22% of patients after Gamma Knife.

Conclusion: Radiotherapy is an effective second-line treatment in patients with Cushing’s disease not cured by surgery. Consideration of the advantages and disadvantages of radiotherapy in comparison with other therapeutic options should always be carried out in the single patient before deciding the second-line therapeutic strategy for persisting or recurring Cushing’s disease.

Background

The treatment of choice for Cushing’s disease is pituitary surgery aimed at complete resection of the adrenocorticotropin (ACTH)-secreting adenoma [1]. In experienced hands, pituitary surgery leads to remission of Cushing’s disease in about 70–90% of cases [2–4]. However, the favorable results of surgery are somewhat weakened by recurrence of disease during long-term follow-up in 10–20% of initially cured patients [2–4]. Second-line treatments include repeat pituitary surgery, radiation therapy, medical therapy, and bilateral adrenalectomy [1].

Different modalities have been developed to irradiate the pituitary. Conventional radiotherapy is delivered in multiple sessions using three fixed radiation beams. Conformation to the shape of the tumor may be achieved by using a multileaf collimator. Radiation doses generally range from 45 to 50 Gy at 180 to 200 cGy per fraction. On the other hand, stereotactic irradiation can be given as a single fraction dose using a multi-headed cobalt unit (Gamma Knife), a linear accelerator, or a proton beam. A
single high dose of radiation is biologically more effective than the same dose delivered in fractions. Thus, a single dose of 20 Gy is biologically equivalent to a fractionated dose of 50 to 110 Gy [5]. However, a single high dose of radiation is also more toxic to normal tissue, particularly to the optic pathway. Therefore, only patients with small tumors that are not in contact with the optic nerves or chiasma are suitable for Gamma Knife treatment. By contrast, conventional radiotherapy can be delivered even to large tumors because fractionation of the total dose lowers the toxicity of radiation to the normal tissue.

Results of Radiotherapy in Cushing’s Disease

Efficacy

The most widely accepted criterion to define remission of hypercortisolism after radiotherapy is normalization of the 24-hour urinary free cortisol concentration. Additional criteria, such as normal basal ACTH and/or cortisol levels and suppression of cortisol secretion after the low-dose dexamethasone test, are variably used.

It must be stressed that normalization of hormone secretion after radiation is time-dependent and an adequate follow-up is necessary before evaluating the outcome. The results of radiotherapy in recent series [6–15] plus our unpublished data are summarized in table 1. Most patients included in these series had previously undergone unsuccessful pituitary surgery or had recurrence of disease, confirming that radiotherapy is almost exclusively used as a second rather than primary choice therapy in Cushing’s disease. The remission rates of hypercortisolism are reasonably homogeneous among the different studies, ranging from 42 to 83%. There seems to be no clear difference according to the type of radiation used. Figure 1 shows our unpublished experience in 49 patients treated by Gamma Knife at our institution. The estimated rate of remission at 5 years is 65.9% (95% CI, 48.9–82.9%). UFC = Urinary free cortisol.

Table 1. Results of selected series of radiotherapy in Cushing’s disease

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Type of radiotherapy</th>
<th>Number of patients</th>
<th>Mean follow-up, years</th>
<th>Dose Gy</th>
<th>Remission rate, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Murayama, 1992</td>
<td>Conventional</td>
<td>20</td>
<td>12</td>
<td>54</td>
<td>55</td>
</tr>
<tr>
<td>Sonino, 1996</td>
<td>Conventional</td>
<td>23</td>
<td>7</td>
<td>50</td>
<td>65</td>
</tr>
<tr>
<td>Tsang, 1996</td>
<td>Conventional</td>
<td>29</td>
<td>7</td>
<td>50</td>
<td>56</td>
</tr>
<tr>
<td>Estrada, 1997</td>
<td>Conventional</td>
<td>30</td>
<td>3.5</td>
<td>50</td>
<td>83</td>
</tr>
<tr>
<td>Nagesser, 2000</td>
<td>Conventional</td>
<td>86</td>
<td>18</td>
<td>50</td>
<td>64</td>
</tr>
<tr>
<td>Hoybye, 2001</td>
<td>Gamma Knife</td>
<td>18</td>
<td>17</td>
<td>NR</td>
<td>83</td>
</tr>
<tr>
<td>Castinetti, 2007</td>
<td>Gamma Knife</td>
<td>40</td>
<td>5</td>
<td>29.5</td>
<td>42</td>
</tr>
<tr>
<td>Jagannathan, 2007</td>
<td>Gamma Knife</td>
<td>90</td>
<td>4</td>
<td>23</td>
<td>54</td>
</tr>
<tr>
<td>Minniti, 2007</td>
<td>Conventional</td>
<td>40</td>
<td>9</td>
<td>45</td>
<td>78</td>
</tr>
<tr>
<td>Petit, 2008</td>
<td>Proton stereotactic</td>
<td>33</td>
<td>5</td>
<td>20</td>
<td>52</td>
</tr>
<tr>
<td>Our series, 2009</td>
<td>Gamma Knife</td>
<td>49</td>
<td>4</td>
<td>25</td>
<td>53</td>
</tr>
</tbody>
</table>

NR = Not reported.

Fig. 1. Kaplan-Meier analysis showing the cumulative rate of remission of hypercortisolism in 49 patients with Cushing’s disease who were treated by Gamma Knife at our institution. The estimated rate of remission at 5 years is 65.9% (95% CI, 48.9–82.9%). UFC = Urinary free cortisol.
Radiation has been reported after either fractionated or single-dose radiotherapy [9, 12–15]. Interestingly, patients with Cushing’s disease seem to have a shorter latency before achieving hormonal remission than patients with acromegaly [16, 17]. At the usual doses of 45–50 Gy, recurrence of hypercortisolism is very infrequent after fractionated radiotherapy, whereas total doses lower than 40 Gy have been associated with the risk of later relapse of disease [18]. Jagannathan et al. [13] reported recurrence of hypercortisolism in 10 of 49 patients who had remission of disease after Gamma Knife, but this experience has not been replicated by others. Control of tumor growth is the rule after radiotherapy, but this experience has not been replicated by others. However, recurrences have been described in patients who had remission of disease after Gamma Knife. The same reasoning applies to the risk of cerebrovascular accidents. Cognitive impairment has been hypothesized to be a long-term sequela of radiation, but no specific data have been collected in patients with Cushing’s disease that have received either fractionated radiotherapy or Gamma Knife.

New-onset hypopituitarism is the most frequent side effect of radiation for pituitary adenomas, including ACTH-secreting tumors. The reported frequency of new-onset hypopituitarism is around 30–50% 4–12 years after fractionated radiotherapy [6, 8, 9, 14]. A lower incidence of hypopituitarism (10% at a median time of 8 years) was reported by Littley et al. [18] who used a median radiation dose of only 20 Gy. However, the reduced rate of hypopituitarism was counterbalanced by a higher risk of recurrence of hypercortisolism in the long term. The mechanism of radiation-induced pituitary dysfunction seems to be mediated by hypothalamic damage. Gamma Knife, by virtue of its more precise delineation of the target and reduced exposure of the surrounding tissue to radiation, should better preserve normal pituitary function, as indirectly suggested in patients with acromegaly [16]. However, in Cushing’s disease the available information is less straightforward. At a median time from Gamma Knife of about 4 years, the rate of new-onset hypopituitarism ranges between 11 and 22% [12, 13, our series]. However, in the series with the longest median follow-up (17 years), Hoybye et al. [11] found that the risk of new-onset hypopituitarism was 66%. The mechanism of radiation-induced hypopituitarism after Gamma Knife should involve direct damage to the pituitary gland and/or pituitary stalk rather than hypothalamic derangement. One of the problems encountered in the Gamma Knife treatment of ACTH-secreting adenomas, which are frequently very small and invisible even with magnetic resonance imaging, is the correct identification of residual tumor. In such cases, it is usual practice to cover the entire sella to be sure to reach the adenomatous tissue and obtain amelioration of Cushing’s disease. The normal pituitary gland is then exposed to a high burden of radiation,
which increases the risk of hypopituitarism. This problematic is seldom encountered in other types of residual pituitary adenomas, such as growth hormone-secreting or nonfunctioning tumors.

Diabetes insipidus has not been reported after radiotherapy for Cushing’s disease.

**Conclusions**

Radiotherapy is an effective second-line treatment in patients with Cushing’s disease not cured by surgery. Remission of hypercortisolism occurs in roughly 50% of irradiated patients, but it takes some time, usually 2–3 years, independently of the technique used (fractionated or single-dose). It is clear that in patients with severe symptoms, the long delay between radiation and efficacy must be considered. Drugs inhibiting the secretion of ACTH and/or cortisol, whether effective and well tolerated, might be very useful to control clinical symptoms while awaiting the effects of radiation.

**References**


**Disclosure Statement**

The authors have nothing to disclose.